ASSEMBLY BIOSCIENCES INC
NASDAQ: ASMB (Assembly Biosciences, Inc.)
最近更新时间: 2小时之前36.60
0.47 (1.30%)
| 前收盘价格 | 36.13 |
| 成交量 | 156,451 |
| 预期市盈率 (P/E Forward) | 16.69 |
| 价格/销量 (P/S) | 7.90 |
| 股市价格/股市净资产 (P/B) | 2.41 |
| 52周波幅 |
| 营业毛利率 | -124.15% |
| 营业利益率 (TTM) | -105.54% |
| 稀释每股收益 (EPS TTM) | -6.20 |
| 季度收入增长率 (YOY) | 62.80% |
| 总债务/股东权益 (D/E MRQ) | 11.13% |
| 流动比率 (MRQ) | 2.05 |
| 营业现金流 (OCF TTM) | -56.19 M |
| 杠杆自由现金流 (LFCF TTM) | -16.50 M |
| 资产报酬率 (ROA TTM) | -25.49% |
| 股东权益报酬率 (ROE TTM) | -133.65% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Assembly Biosciences, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.17 |
|
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 39.25% |
| 机构持股比例 | 12.77% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Seven Fleet Capital Management Lp | 30 Jun 2026 | 433,147 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合